| Management target | Revenue 32.5% FY28 |
|---|
| Revenue growth | 31.2% YoY growth in Q1 FY27. |
|---|---|
| Margins | EBITDA impacted by leadership hires and remediation costs; mid-teens target post-EU. |
| Order book | Received first product order from Australia. |
| Demand visibility | Strong export resilience; expectations for EU market supplies by Q4. |
| Management confidence | High, pending EU-GMP certification finalization. |
Growth
Revenue reached INR 942 million (+31.2% YoY). EBITDA stood at INR 34 million with 3.7% margin; PAT was a loss of INR 40 million.
Outlook
Management guides 30-35% revenue growth for FY28 post-EU-GMP; FY27 growth expected at 10-15% without EU. Capex of INR 15-20Cr planned.
Risks
Primary risk remains the timeline for EU-GMP certification; Middle East geopolitical disruptions showed some initial impact.
Last quarter's promises, checked
Delivered
- Guided EU-GMP inspection in May 2026 → delivered May 4-7 2026 (= BEAT)
- Guided NIP/OTF revenue recovery in Q4 → delivered INR 254M (+sequential recovery) (= BEAT)
- Guided senior leadership expansion → delivered 3 VPs & 1 President hired (= BEAT)
Partly delivered
- Guided EU-GMP reinstatement process → delivered inspection complete, awaiting final report (= PARTIAL)
Missed
- Guided FY26 Revenue broadly in line with FY25 → delivered INR 3,744M (impacted by INR 200-250M MENA loss) (= MISS)
Investor Presentation filed with BSE, NSE: ZIMLAB. Summary written with AI assistance from the document.
Zim Laboratories Ltd: key numbers
- Share price
- ₹146.61
- Market cap
- ₹786.7 Cr
- Revenue (annual)
- ₹374.4 Cr
- Net profit (annual)
- ₹5.84 Cr
- P/E (TTM)
- 212.8×Sector 47.3×
- Promoter holding
- 30.36%+0.01% QoQ
- FII holding
- 0.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zim Laboratories Ltd
All →Zim Laboratories Merger & Restructuring Worth ₹1,404,640 Cr
ZIM Laboratories completed incorporation of its wholly-owned Chilean subsidiary, ZIM Laboratories SpA. The LATAM expansion entity is now operational, marking completion of the February 2026 board-approved plan.
- Value
- ₹14,04,640 Cr
Zim Laboratories Merger & Restructuring
ZIM Laboratories Limited incorporated a wholly owned subsidiary, 'ZIM Laboratories SpA', in Chile. This expansion aims to develop its pharmaceutical business in the LATAM region.
Zim Laboratories Acquisition Worth ₹1.56 Cr
ZIM WOS completed a ₹1.56 Crore investment in stepdown ZIM Scientific Office L.L.C., Dubai, fulfilling the board-approved capital plan. The transaction closes the acquisition announced in August 2025.
- Value
- ₹1.56 Cr
Zim Laboratories Merger & Restructuring Worth ₹2.38 Cr
Zim Laboratories confirmed that its subsidiary, ZIM FZE, completed the previously announced AED 9,16,000 investment in its step-down subsidiary, ZIM Scientific Office LLC.
- Value
- ₹2.38 Cr
Zim Laboratories Other Announcement
A periodic shareholding pattern filing for Zim Laboratories Ltd for the quarter ended March 31, 2026, disclosing promoter and public shareholding details.
Zim Laboratories Annual General Meeting
Zim Laboratories Limited has announced the successful passing of Special Resolutions through a postal ballot, approving the remuneration structure for its Managing and Whole-Time Directors.